Laxative Effects of Aqueous Extract of Sida acuta Leaves in Loperamide- Induced Constipation in Wistar Rats

Chukwuemeka, Nweje Anyalowu Paul; Adejoh, Idakwoji Precious; Osafanme, Iserhienrhien Lucky; Duniya, Sheneni Victor; Boniface, Momoh Theophilus

doi:10.9734/ajrimps/2019/v6i130093

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Changes in fecal pellet number, weight, and water content in rats with loperamide-induced constipation are important factors that need to be improved while aiming to relieve constipation. Previous studies have reported a marked reduction in the fecal pellet count, weight, and water content, in rats treated with loperamide [ 22 , 23 ], whereas prebiotic intake is known to improve the fecal parameters [ 24 , 25 ]. The MOS used in this study also improved the fecal pellet number and water content (Figures 2 and 3 ).…”

Section: Discussionmentioning

confidence: 99%

Amylase‐Producing Maltooligosaccharide Provides Potential Relief in Rats with Loperamide‐Induced Constipation

Jang

Kim

Suh

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Constipation is a chronic disease caused by infrequent, inadequate, and difficult bowel movements. The present study aimed to evaluate the potential laxative effect of maltooligosaccharide (MOS) on loperamide-induced constipation in a rat model. In vitro experiments were conducted to evaluate the effect of MOS on the growth of lactic acid bacteria. Moreover, to examine the effect of MOS administration on Sprague-Dawley (SD) rats with loperamide-induced constipation, the drinking water for the rats was supplemented with 10% or 15% of MOS for 14 days, and, thereafter, the improvement in constipation was assessed. For this, the rats were divided into five groups: normal (Nor), loperamide-induced constipated (Con), positive control (15% of dual-oligosaccharide (DuO-15)), 10% MOS treated (MOS-10), and 15% MOS-treated (MOS-15). In an in vitro test, MOS treatment promoted the growth of lactic acid bacteria except Lactobacillus bulgaricus. Treatment with higher MOS dose relieved constipation in rats by improving the fecal pellet and water content. Furthermore, in the high MOS dose group, the cecal short-chain fatty acid levels significantly increased compared to those in the control group (P<0.001). MOS treatment also improved the mucosal thickness as well as mucin secretion and increased the area of intestinal Cajal cells compared to that in the control group (P<0.001). These findings suggest that MOS relieves constipation and has beneficial effect on the gastrointestinal tract, and, therefore, it can be used as an ingredient in functional foods for treating constipation or improving intestinal health.

show abstract